Lirafugratinib (Lyrfigtu)

Name: Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Disease description
Published: 2026-09-27T09:44:05-04:00

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008

Manufacturer: Elevar Therapeutics
Regulatory submission: NDA submitted January 2026
Launch: Anticipated in the fourth quarter of 2026
Last updated: October 1, 2026

Section

Product information and disease description Place of product in therapy

Disease description

140 evidence topics · 56 sources

Definition and etiology10 evidence topics · 9 sources
Epidemiology27 evidence topics · 21 sources
Natural history, survival, and mortality21 evidence topics · 16 sources
Pathophysiology13 evidence topics · 13 sources
Diagnosis26 evidence topics · 21 sources
Clinical presentation - signs and symptoms6 evidence topics · 5 sources
Long-term morbidity6 evidence topics · 5 sources
Burden of Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma31 evidence topics · 19 sources